deltatrials
Completed PHASE2 NCT00090090

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Sponsor: Spectrum Pharmaceuticals, Inc

Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma
Interventions Elsamitrucin
Updated 5 times since 2017 Last updated: Jan 8, 2008 Started: Apr 30, 2004 Completion: Oct 31, 2006

This PHASE2 trial investigates Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell Lymphoma and is currently completed. Spectrum Pharmaceuticals, Inc leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Spectrum Pharmaceuticals, Inc
Data source: Spectrum Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Berkeley, United States
  • • Burbank, United States
  • • Los Angeles, United States
  • • Manhasset, United States
  • • Mission Hills, United States
  • • Rancho Mirage, United States